Je-Vax Articles
Acambis' JE vacc meets Ph III efficacy endpoint
12 March 2007
Strong safety and efficacy data for ChimeriVax-JE
6 November 2006
Intercell's JEV vaccine performs well in study
12 June 2006
Enrollment in Ph III JE vacc trials complete
24 April 2006
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
Showing 1-5 of 5 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
